Trier Research Laboratories

Trier Research Laboratories is a specialized biotechnology research entity founded by Dr. Klaus Trier in 1993, focusing on connective tissue and ophthalmology. The company's primary innovation is the use of 7-methylxanthine (7-MX), a caffeine metabolite and non-selective adenosine receptor antagonist, to slow the progression of childhood myopia by increasing the biomechanical strength of the sclera. While 7-MX has been licensed and used in Denmark since 2009, the company has partnered with Theialife Sciences to advance the treatment (designated as ND10) into global Phase 3 clinical trials. Beyond myopia, the company's pipeline includes preclinical programs for keratoconus, UV-B cataract prevention, and other ocular conditions.